Last reviewed · How we verify

CAL101

Calluna Pharma AS · Phase 2 active Small molecule

CAL101 is a phosphatidylinositol 3-kinase (PI3K) delta inhibitor that selectively blocks PI3K signaling in immune cells to modulate immune responses.

CAL101 is a phosphatidylinositol 3-kinase (PI3K) delta inhibitor that selectively blocks PI3K signaling in immune cells to modulate immune responses. Used for B-cell malignancies (in development).

At a glance

Generic nameCAL101
SponsorCalluna Pharma AS
Drug classPI3K delta inhibitor
TargetPI3K delta (PIK3CD)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

CAL101 inhibits the delta isoform of PI3K, an enzyme critical for B-cell and T-cell activation and survival. By blocking PI3K delta signaling, the drug reduces proliferation and activation of malignant B cells and modulates immune cell function, making it potentially useful in hematologic malignancies and immune-mediated disorders. This selective inhibition of the delta isoform aims to minimize toxicity compared to pan-PI3K inhibitors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results